11/10/2014 - 5:01pm

Greenstone announced the launch of sirolimus tablets. The product is offered in 1-mg and 2-mg dosage strengths in bottles of 100 tablets each. 

11/10/2014 - 11:40am

Eli Lilly and Co. on Monday announced that its Type 2 diabetes treatment drug Trulicity (dulaglutide) , is now available in U.S. pharmacies. The drug is a once-weekly glucagon-like peptide-1 receptor agonist, and comes in a single-dose pen, which doesn't require the patient to mix, measure or handle the needle, the company said.

11/10/2014 - 9:21am

Sandoz last week announced the launch of a generic version of cyclophosphamide injection, USP. Sandoz is launching the drug through collaboration with Jiangsu Hengrui Medicine Co., which owns the product's abbreviated new drug application. 

11/07/2014 - 1:30pm

Janssen Therapeutics announced earlier this week that the Food and Drug Administration approved Olysio (simeprevir), a hepatitis C virus NS3/4A protease inhibitor, in combination with sofosbuvir as an all-oral, interferon- and ribavirin-free treatment option for genotype 1 chronic hepatitis C (CHC) infection in adult patients as part of a combination antiviral treatment regimen. 

11/06/2014 - 10:10am

Mylan announced the launch of norethindrone acetate and ethinyl estradiol tablets USP, 1 mg/0.02 mg and ferrous fumarate, which is the generic equivalent to Loestrin 24 Fe from Warner Chilcott. 

11/03/2014 - 10:25am

Protein Sciences Corp. last week announced that the Food and Drug Administration approved Flublok influenza vaccine for all adults ages 18 years and older.

10/31/2014 - 10:08am

Novo Nordisk announced the launch of NovoFine Plus in the United States. NovoFine Plus is a universal needle that works with all currently available insulin, as well as some GLP-1 receptor agonist pens, the company said. 

 

10/31/2014 - 9:35am

Mylan on Friday announced the launch of nevirapine extended-release tablets in 400-mg strength, a generic version of Viramune XR from Boehringer Ingelheim. 

10/30/2014 - 11:54am

AstraZeneca on Thursday announced that the Food and Drug Administration approved Xigduo XR (dapagliflozin and metformin hydrochloride extended-release), a once-daily drug for the treatment of adults with Type 2 diabetes.